Skip Navigation
Department of Health and Human Services www.hhs.gov
 
Slide Tray
0 slides

Return to Slide Library

Slides

Add Presentation to Slide Tray Presentation:

Drug Therapy for Rheumatoid Arthritis in Adults

Slide: 33 of 45

Summary of Benefits: DMARD Combinations Versus Monotherapies (2 of 2)

In patients whose rheumatoid arthritis failed to respond to methotrexate (MTX), combination therapy with MTX and a biologic disease-modifying anti-rheumatic drug (DMARD) was not more successful than monotherapy with a biologic DMARD.  The strength of evidence for this finding is moderate.

In MTX-naïve patients or those not taken MTX recently, combination therapy is superior to monotherapy with a biologic DMARD for functional capacity  and quality of life. The strength of evidence for functional capacity is moderate and for quality of life is low.